Baidu
map

Lancet:Burosumab可明显改善X染色体连锁的低磷血症患儿的佝偻病表现

2019-05-20 QQ MedSci原创

儿童X性染色体连锁的低磷血症的特点是血清成纤维细胞生长因子23 (FGF23)浓度升高、低磷血症、佝偻病、下肢弯曲和生长障碍。研究人员对比由口服磷酸盐和活性VitD组成的常规持续疗法与改用burosumab(布罗沙单抗,一种抗FGF23的全人单克隆抗体)治疗儿童X染色体连锁的低磷酸盐血症的疗效和安全性。研究人员在16个医疗中心开展一随机的、活性对照的开放性3期临床试验,招募1-12岁的X染色体连锁

儿童X性染色体连锁的低磷血症的特点是血清成纤维细胞生长因子23 (FGF23)浓度升高、低磷血症、佝偻病、下肢弯曲和生长障碍。研究人员对比由口服磷酸盐和活性VitD组成的常规持续疗法与改用burosumab(布罗沙单抗,一种抗FGF23的全人单克隆抗体)治疗儿童X染色体连锁的低磷酸盐血症的疗效和安全性。

研究人员在16个医疗中心开展一随机的、活性对照的开放性3期临床试验,招募1-12岁的X染色体连锁的低磷酸盐血症患儿。要求:佝偻病严重程度评分至少为2.0、空腹血清磷<0.97mmol/L(3.0 mg/dL)、证实PHEX(磷酸盐调节肽同源物,X染色体连锁)突变或携带意义不明的变异,3岁以下的儿童至少采取传统疗法连续治疗6个月,3岁以上的儿童至少采取传统疗法治疗过12个月。受试患者(1:1)被随机分至burosumab组(0.8 mg/kg·2周)或传统疗法组。持续治疗64周。主要结点是第40周时佝偻病的改善情况。

2016年8月3日-2017年5月8日共招募了61位患儿,32位(18位女生)被分至传统疗法组,29位(16位女生)被分至burosumab组。第40周时,与传统疗法组相比,burosumab组的患者的佝偻病明显改善(burosumab组评分升高1.9[SE 0.1] vs 传统疗法组评分升高0.8[0.1];差值 1.1,95% CI 0.8-1.5;p<0.0001)。burosumab组的不良事件多于传统疗法组(17例[59%] vs 7例[22%])。两组各发生3例重度副反应,均认定与治疗无关。

本研究表明,与传统治疗方法相比,burosumab治疗X染色体连锁的低磷血症儿童佝偻病的严重程度、生长和生物化学特性均有显著改善。

原始出处:

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1951869, encodeId=fcc81951869e7, content=<a href='/topic/show?id=8cb2188852b' target=_blank style='color:#2F92EE;'>#X染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18885, encryptionId=8cb2188852b, topicName=X染色体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Mon Feb 03 07:59:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830079, encodeId=8b3618300e903, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Mar 11 13:59:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668805, encodeId=0543166880566, content=<a href='/topic/show?id=3aad3e9530' target=_blank style='color:#2F92EE;'>#Burosumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3795, encryptionId=3aad3e9530, topicName=Burosumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7db326440501, createdName=xuqianhua, createdTime=Sun Nov 03 07:59:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912139, encodeId=b86c191213921, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Oct 17 15:59:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331710, encodeId=955f1331e102e, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341362, encodeId=3a50134136284, content=<a href='/topic/show?id=001d26e84b9' target=_blank style='color:#2F92EE;'>#佝偻病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26784, encryptionId=001d26e84b9, topicName=佝偻病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364488, encodeId=aa771364488ff, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531007, encodeId=0e2d153100ef5, content=<a href='/topic/show?id=e80b26301b6' target=_blank style='color:#2F92EE;'>#低磷血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26301, encryptionId=e80b26301b6, topicName=低磷血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7f312187038, createdName=medscijoin, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1951869, encodeId=fcc81951869e7, content=<a href='/topic/show?id=8cb2188852b' target=_blank style='color:#2F92EE;'>#X染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18885, encryptionId=8cb2188852b, topicName=X染色体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Mon Feb 03 07:59:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830079, encodeId=8b3618300e903, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Mar 11 13:59:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668805, encodeId=0543166880566, content=<a href='/topic/show?id=3aad3e9530' target=_blank style='color:#2F92EE;'>#Burosumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3795, encryptionId=3aad3e9530, topicName=Burosumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7db326440501, createdName=xuqianhua, createdTime=Sun Nov 03 07:59:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912139, encodeId=b86c191213921, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Oct 17 15:59:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331710, encodeId=955f1331e102e, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341362, encodeId=3a50134136284, content=<a href='/topic/show?id=001d26e84b9' target=_blank style='color:#2F92EE;'>#佝偻病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26784, encryptionId=001d26e84b9, topicName=佝偻病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364488, encodeId=aa771364488ff, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531007, encodeId=0e2d153100ef5, content=<a href='/topic/show?id=e80b26301b6' target=_blank style='color:#2F92EE;'>#低磷血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26301, encryptionId=e80b26301b6, topicName=低磷血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7f312187038, createdName=medscijoin, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
    2020-03-11 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1951869, encodeId=fcc81951869e7, content=<a href='/topic/show?id=8cb2188852b' target=_blank style='color:#2F92EE;'>#X染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18885, encryptionId=8cb2188852b, topicName=X染色体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Mon Feb 03 07:59:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830079, encodeId=8b3618300e903, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Mar 11 13:59:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668805, encodeId=0543166880566, content=<a href='/topic/show?id=3aad3e9530' target=_blank style='color:#2F92EE;'>#Burosumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3795, encryptionId=3aad3e9530, topicName=Burosumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7db326440501, createdName=xuqianhua, createdTime=Sun Nov 03 07:59:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912139, encodeId=b86c191213921, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Oct 17 15:59:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331710, encodeId=955f1331e102e, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341362, encodeId=3a50134136284, content=<a href='/topic/show?id=001d26e84b9' target=_blank style='color:#2F92EE;'>#佝偻病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26784, encryptionId=001d26e84b9, topicName=佝偻病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364488, encodeId=aa771364488ff, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531007, encodeId=0e2d153100ef5, content=<a href='/topic/show?id=e80b26301b6' target=_blank style='color:#2F92EE;'>#低磷血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26301, encryptionId=e80b26301b6, topicName=低磷血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7f312187038, createdName=medscijoin, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1951869, encodeId=fcc81951869e7, content=<a href='/topic/show?id=8cb2188852b' target=_blank style='color:#2F92EE;'>#X染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18885, encryptionId=8cb2188852b, topicName=X染色体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Mon Feb 03 07:59:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830079, encodeId=8b3618300e903, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Mar 11 13:59:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668805, encodeId=0543166880566, content=<a href='/topic/show?id=3aad3e9530' target=_blank style='color:#2F92EE;'>#Burosumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3795, encryptionId=3aad3e9530, topicName=Burosumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7db326440501, createdName=xuqianhua, createdTime=Sun Nov 03 07:59:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912139, encodeId=b86c191213921, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Oct 17 15:59:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331710, encodeId=955f1331e102e, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341362, encodeId=3a50134136284, content=<a href='/topic/show?id=001d26e84b9' target=_blank style='color:#2F92EE;'>#佝偻病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26784, encryptionId=001d26e84b9, topicName=佝偻病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364488, encodeId=aa771364488ff, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531007, encodeId=0e2d153100ef5, content=<a href='/topic/show?id=e80b26301b6' target=_blank style='color:#2F92EE;'>#低磷血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26301, encryptionId=e80b26301b6, topicName=低磷血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7f312187038, createdName=medscijoin, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
    2019-10-17 snf701207
  5. [GetPortalCommentsPageByObjectIdResponse(id=1951869, encodeId=fcc81951869e7, content=<a href='/topic/show?id=8cb2188852b' target=_blank style='color:#2F92EE;'>#X染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18885, encryptionId=8cb2188852b, topicName=X染色体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Mon Feb 03 07:59:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830079, encodeId=8b3618300e903, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Mar 11 13:59:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668805, encodeId=0543166880566, content=<a href='/topic/show?id=3aad3e9530' target=_blank style='color:#2F92EE;'>#Burosumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3795, encryptionId=3aad3e9530, topicName=Burosumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7db326440501, createdName=xuqianhua, createdTime=Sun Nov 03 07:59:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912139, encodeId=b86c191213921, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Oct 17 15:59:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331710, encodeId=955f1331e102e, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341362, encodeId=3a50134136284, content=<a href='/topic/show?id=001d26e84b9' target=_blank style='color:#2F92EE;'>#佝偻病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26784, encryptionId=001d26e84b9, topicName=佝偻病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364488, encodeId=aa771364488ff, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531007, encodeId=0e2d153100ef5, content=<a href='/topic/show?id=e80b26301b6' target=_blank style='color:#2F92EE;'>#低磷血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26301, encryptionId=e80b26301b6, topicName=低磷血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7f312187038, createdName=medscijoin, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1951869, encodeId=fcc81951869e7, content=<a href='/topic/show?id=8cb2188852b' target=_blank style='color:#2F92EE;'>#X染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18885, encryptionId=8cb2188852b, topicName=X染色体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Mon Feb 03 07:59:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830079, encodeId=8b3618300e903, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Mar 11 13:59:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668805, encodeId=0543166880566, content=<a href='/topic/show?id=3aad3e9530' target=_blank style='color:#2F92EE;'>#Burosumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3795, encryptionId=3aad3e9530, topicName=Burosumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7db326440501, createdName=xuqianhua, createdTime=Sun Nov 03 07:59:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912139, encodeId=b86c191213921, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Oct 17 15:59:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331710, encodeId=955f1331e102e, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341362, encodeId=3a50134136284, content=<a href='/topic/show?id=001d26e84b9' target=_blank style='color:#2F92EE;'>#佝偻病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26784, encryptionId=001d26e84b9, topicName=佝偻病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364488, encodeId=aa771364488ff, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531007, encodeId=0e2d153100ef5, content=<a href='/topic/show?id=e80b26301b6' target=_blank style='color:#2F92EE;'>#低磷血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26301, encryptionId=e80b26301b6, topicName=低磷血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7f312187038, createdName=medscijoin, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1951869, encodeId=fcc81951869e7, content=<a href='/topic/show?id=8cb2188852b' target=_blank style='color:#2F92EE;'>#X染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18885, encryptionId=8cb2188852b, topicName=X染色体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Mon Feb 03 07:59:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830079, encodeId=8b3618300e903, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Mar 11 13:59:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668805, encodeId=0543166880566, content=<a href='/topic/show?id=3aad3e9530' target=_blank style='color:#2F92EE;'>#Burosumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3795, encryptionId=3aad3e9530, topicName=Burosumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7db326440501, createdName=xuqianhua, createdTime=Sun Nov 03 07:59:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912139, encodeId=b86c191213921, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Oct 17 15:59:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331710, encodeId=955f1331e102e, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341362, encodeId=3a50134136284, content=<a href='/topic/show?id=001d26e84b9' target=_blank style='color:#2F92EE;'>#佝偻病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26784, encryptionId=001d26e84b9, topicName=佝偻病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364488, encodeId=aa771364488ff, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531007, encodeId=0e2d153100ef5, content=<a href='/topic/show?id=e80b26301b6' target=_blank style='color:#2F92EE;'>#低磷血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26301, encryptionId=e80b26301b6, topicName=低磷血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7f312187038, createdName=medscijoin, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]
    2019-05-22 lsndxfj
  8. [GetPortalCommentsPageByObjectIdResponse(id=1951869, encodeId=fcc81951869e7, content=<a href='/topic/show?id=8cb2188852b' target=_blank style='color:#2F92EE;'>#X染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18885, encryptionId=8cb2188852b, topicName=X染色体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=845e216, createdName=cqlidoudou, createdTime=Mon Feb 03 07:59:00 CST 2020, time=2020-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830079, encodeId=8b3618300e903, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Mar 11 13:59:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668805, encodeId=0543166880566, content=<a href='/topic/show?id=3aad3e9530' target=_blank style='color:#2F92EE;'>#Burosumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3795, encryptionId=3aad3e9530, topicName=Burosumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7db326440501, createdName=xuqianhua, createdTime=Sun Nov 03 07:59:00 CST 2019, time=2019-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912139, encodeId=b86c191213921, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Oct 17 15:59:00 CST 2019, time=2019-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331710, encodeId=955f1331e102e, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341362, encodeId=3a50134136284, content=<a href='/topic/show?id=001d26e84b9' target=_blank style='color:#2F92EE;'>#佝偻病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26784, encryptionId=001d26e84b9, topicName=佝偻病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eb32500176, createdName=luckyshitiancai_42705684, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364488, encodeId=aa771364488ff, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531007, encodeId=0e2d153100ef5, content=<a href='/topic/show?id=e80b26301b6' target=_blank style='color:#2F92EE;'>#低磷血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26301, encryptionId=e80b26301b6, topicName=低磷血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7f312187038, createdName=medscijoin, createdTime=Wed May 22 11:59:00 CST 2019, time=2019-05-22, status=1, ipAttribution=)]

相关资讯

FDA批准**遗传佝偻病药物burosumab

新闻事件今天FDA批准了Ultragenyx(RARE)/ Kyowa Kirin合作开发的FGF23抗体burosumab(商品名Crysvita?)用于治疗一岁以上X-连锁低磷性佝偻病(XLH)。这是美国首款上市的XLH药物,也是RARE继Mepsevii后6个月内上市的第二个首创新药。Crysvita此前获得FDA突破性药物地位和优先审批资格,RARE因此将再获得一张优先评审券(PRV),因

孩子出汗多,你如何应对?

很多孩子都有出汗多的现象,吃奶、睡觉时出汗就更多了,更别说在这酷热难当的盛夏季节。家里有宝宝的医生爸妈们,你们是否为此困惑以及担心过? 那么,来听听常年在临床一线工作的儿保医生们给的建议吧。

佝偻病,不止维生素D缺乏那么简单!

佝偻病是婴幼儿时期常见的一种慢性疾病,是由于钙磷代谢异常引起骨矿化不全所致,初期可表现为夜惊、多汗、枕凸,随后逐渐出现骨骼发育方面的问题,比如颅骨软化、手足镯、方颅、肋骨串珠、胸廓畸形、O形或X形腿,一些宝宝还表现为出牙晚,囟门闭合延迟,有的宝宝在病程中由于低钙还可出现抽搐。典型的X片表现可见长骨干骺端增宽,成杯口状,边缘毛糙;血生化可见血钙、血磷降低,碱性磷酸酶升高;25-羟维生素D及1,2

维生素D胶囊,一粒就好,对吗?

越来越多的人摄入了过多的维生素D,似乎人们都不会嫌自己维生素摄入过多,就像在炎热的夏天吃冰淇淋一样。当然,从技术角度讲,是会吃多的,但这个上限非常高,而且,最坏会发生什么情况呢?而且,与冰淇淋不同的是,我们都知道维生素是有益健康的。

NEJM:Burosumab治疗X-连锁低磷血症效果显著

研究发现Burosumab可改善X-连锁低磷血症患儿肾小管磷酸再吸收能力,增加血清磷水平,增加身高,恢复身体机能,减轻疼痛和佝偻程度

Baidu
map
Baidu
map
Baidu
map